Study identification

EU PAS number

EUPAS8718

Study ID

18489

Official title and acronym

Post-marketing Study Assessing the Long-term Safety of Abatacept

DARWIN EU® study

No

Study countries

United States

Study description

This is a retrospective cohort study that will be conducted using administrative health care databases in the United States to estimate and compare the risk of malignancies and infections among patients exposed to abatacept and patients exposed to other treatments for rheumatoid arthritis (RA).

Study status

Finalised
Research institutions and networks

Institutions

Contact details

Nicole Baker

Primary lead investigator
Study timelines

Date when funding contract was signed

Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Bristol-Myers Squibb
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable